Finanzas de Bioventus Inc. (BVS)BVSBioventus Inc.

Bioventus Inc. (BVS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pain Treatments, accounting for 48.0% of total sales, equivalent to $63.43M. Other significant revenue streams include Surgical solutions and Restorative Therapies. Understanding this composition is critical for investors evaluating how BVS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Bioventus Inc. maintains a gross margin of 68.29%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.42%, while the net margin is 23.63%. These profitability ratios, combined with a Return on Equity (ROE) of 27.96%, provide a clear picture of how effectively BVS converts its operational activities into shareholder value.

In the context of the broader market, BVS competes directly with industry leaders such as DRTS and ENOV. With a market capitalization of $1.26B, it holds a leading position in the sector. When comparing efficiency, BVS's gross margin of 68.29% stands against DRTS's N/A and ENOV's 54.51%. Such benchmarking helps identify whether Bioventus Inc. is trading at a premium or discount relative to its financial performance.

Bioventus reported Q2 revenue of $153 million, a 4% year-over-year increase, and a significant net income of $33.4 million in Q2 2026, reflecting a strong recovery and operational efficiency.